Johnson & Johnson vs Novo Nordisk A/S — Stock Comparison
Johnson & Johnson (JNJ) and Novo Nordisk A/S (NVO) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Novo Nordisk A/S on Q·Score (6.9 vs 6.3 out of 10), led by Sentiment (7.4 vs 4) and Growth (5 vs 3.8). Novo Nordisk A/S scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst price targets imply similar upside for both: -0.2% for JNJ and +1.1% for NVO.
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
High-quality business with 60% return on equity and 35% profit margins.
⚠ earnings contracting 21% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs NVO: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 6.9/10 versus Novo Nordisk A/S (NVO) at 6.3/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or NVO?
Johnson & Johnson (JNJ) scores higher on Growth (5/10 vs 3.8/10). Johnson & Johnson reports revenue growth (6.6% YoY) while Novo Nordisk A/S reports (2.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or NVO more attractively valued?
Novo Nordisk A/S (NVO) scores higher on Valuation (6.5/10 vs 5.8/10). JNJ trades at 22.2× P/E versus NVO at 13.6×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs NVO?
There are 22 analysts covering JNJ with a consensus price target of $272.50, and 12 analysts covering NVO with a consensus target of $47.42. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or NVO?
Novo Nordisk A/S (NVO) scores higher on Quality (10/10 vs 9.3/10). Net profit margin: JNJ at 21.5%, NVO at 35.3%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or NVO?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.9/10). Market beta: JNJ at 0.23, NVO at 0.35. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and NVO?
Johnson & Johnson (JNJ) has a market capitalisation of $658.0B, while Novo Nordisk A/S (NVO) has a market cap of $207.5B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or NVO pay dividends?
JNJ pays a dividend yield of 1.96%, while NVO pays a dividend yield of 3.83%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →